Cubist Pharmaceuticals to Present at September Investor Conferences.LEXINGTON, Mass. -- Cubist Pharmaceuticals, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : CBST CBST Center for Biophotonics Science and Technology CBST Congregation Beth Simcha Torah (NYC) CBST Complete Binary Search Tree ) today announced that company management will present at four investor conferences during September to discuss the company's business activities, financial outlook, and current news. * Robert Perez, EVP and COO, will present on Wednesday, September 9, at 8:00 a.m. Eastern Time, at the Thomas Weisel Partners Thomas Weisel Partners Group, Inc. (NASDAQ: TWPG), often shortened to just TWP or TWeisel, is a U.S. middle-market and growth focused investment banking firm based in San Francisco, California. Healthcare Conference being held at the Four Seasons Hotel in Boston. (Live audio-only webcast.) * Steven Gilman, SVP and CSO, will present on Wednesday, September 16, at 1:45 p.m. Pacific Time, at the 6th Annual ThinkEquity Conference being held at the St. Regis Hotel in San Francisco. (Live audio with slides webcast.) * Michael Bonney, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , will present on Monday, September 21, at 4 p.m. Eastern Time, at UBS Global Life Sciences Conference being held at the Grand Hyatt in New York City New York City: see New York, city. New York City City (pop., 2000: 8,008,278), southeastern New York, at the mouth of the Hudson River. The largest city in the U.S. . (Live audio with slides webcast.) * David McGirr, SVP and CFO See Chief Financial Officer. , will present on Tuesday, September 22, at 8:50 a.m. Eastern Time, at the Banc of America Merrill Lynch Conference being held at the InterContinental Hotel in Boston. (Live audio with slides webcast.) All of the presentations are accessible through Cubist's website at www.cubist.com in the Investor Relations Conference Calendar section and will be available there for a period of 30 days after the presentations. About Cubist Cubist Pharmaceuticals, Inc. is a biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. In the U.S., Cubist markets CUBICIN[R] (daptomycin for injection), the first antibiotic in a new class of anti-infectives called lipopeptides. In July 2008, Cubist entered into an agreement with AstraZeneca to promote their established antibiotic, MERREM[R] I.V. (meropenem for injection) in the U.S. The Cubist product pipeline includes ecallantide, a recombinant human protein in Phase 2 clinical trials -- CONSERV[TM]-1 and CONSERV[TM]-2 -- for the reduction of blood loss during cardiac surgery, and two Phase 1 programs that address unmet medical needs, one in CDAD CDAD Clostridium Difficile-Associated Diarrhea CDAD Component Data Administrator (Clostridium difficile-associated diarrhea) and the other in multi-drug resistant (MDR MDR, n See multidrug resistance. MDR, n the abbreviation for minimum daily requirement, specifically the Minimum Daily Requirements for Specific Nutrients compiled by the United States Food and Drug Administration. ) Gram-negative infections. In addition, the Company, in collaboration with Alnylam Pharmaceuticals, Inc. (Cambridge, MA), has a pre-IND and a Phase 2 program underway in novel treatments for respiratory syncytial virus infections using Alnylam's RNA-interference technology. Cubist is headquartered in Lexington, MA. Additional information can be found at Cubist's web site at www.cubist.com. Cubist and CUBICIN are registered trademarks of Cubist Pharmaceuticals, Inc. AstraZeneca and MERREM are registered trademarks of the AstraZeneca group of companies. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion